Selank

Assumed/theoretical. Selank is a synthetic heptapeptide analog of the endogenous immune peptide tuftsin (Thr-Lys-Pro-Arg), extended with Pro-Gly-Pro to slow enzymatic breakdown. Its proposed anxiolytic/nootropic action is attributed to modulation of GABAergic and monoaminergic (serotonin/dopamine) signaling, changes in BDNF expression, and inhibition of enkephalin-degrading enzymes (raising endogenous enkephalin tone), alongside immunomodulatory effects on cytokines such as IL-6. None of these mechanisms is confirmed in controlled human studies; treat them as hypotheses carried over from animal/in-vitro work.

The trials compared Selank with a benzodiazepine, so 'worked' means similar relief to that drug, not better than placebo.

Adverse events

In the small published Russian trials, adverse events were mild and transient, most commonly local nasal/sinus irritation and headache from the intranasal route, occasionally fatigue or dizziness. No serious adverse events were reported in the published trials, and unlike benzodiazepines no sedation, psychomotor impairment, dependence, or withdrawal was described.

Contraindications

No formally established contraindications because no Western regulatory label exists. There is explicitly NO human safety data in pregnancy, lactation, or childhood, and Russian study protocols excluded participants under 18; these groups should be treated as contraindicated by default. US 'research chemical' supply carries purity, sterility, and mislabeling risk independent of the molecule itself.

Theoretical concerns

As a peptide that may modulate serotonergic, GABAergic and enkephalin/opioid-related signaling, theoretical interactions with SSRIs, benzodiazepines, or other CNS-active drugs cannot be excluded, though none are well characterized. As an immunomodulatory tuftsin analog it could in theory influence cytokine/immune tone (IL-6, T-helper balance), with unknown clinical relevance.

What nobody knows yet

No long-term human safety data, no Western pharmacovigilance, and no large or placebo-controlled trials. Real-world purity/dose accuracy of gray-market vials is unverified. Whether intranasal self-dosing reproduces the pharmacology seen in supervised Russian trials is unknown. Effect sizes versus true placebo are entirely uncharacterized.

What else could explain the result

Selank is very commonly co-administered with Semax (and sometimes with SSRIs, phenibut, caffeine, or other nootropics), which makes it nearly impossible for users to attribute any calm-focus effect to Selank specifically. Concurrent therapy, exercise, sleep changes, and the strong subjective expectancy around 'a Russian anti-anxiety peptide' all muddy attribution.

Is the vial what it says?

Cross-checked against PubMed (confirmed real human clinical trials exist: 2008 n=62 vs medazepam, 2014 n=60 vs phenazepam, 2015 augmentation, plus a 2020 imaging study, all small, Russian, none placebo-controlled), a PubMed search confirming zero double-blind placebo-controlled trials, ClinicalTrials.gov (no Selank-specific registrations, only incidental keyword matches), Wikipedia (sequence/tuftsin derivation/Institute of Molecular Genetics origin), and FDA 503A bulks-list reporting (removed from Category 2 effective 2024-09-27). A circulating '47% vs 34% placebo' figure could not be tied to any indexed placebo-controlled trial and is treated as unverified.

Half-life and storage

Half-life: Very short in plasma, reported on the order of only a few minutes (commonly cited as roughly 2-3 minutes, with some sources citing under 2 minutes) due to rapid peptidase degradation. This is precisely why dosing is intranasal: the nose-to-brain (olfactory/trigeminal) route delivers peptide to the CNS before systemic enzymes clear it. Subjective CNS effects are anecdotally reported to last several hours per dose, but that duration is not a measured plasma half-life.

Once mixed: Supplied as a lyophilized powder requiring reconstitution with bacteriostatic water. Handle as a fragile peptide: keep lyophilized vials cold/frozen until use, refrigerate after reconstitution, and protect from heat, light, and repeated freeze-thaw. Reconstituted solution is anecdotally reported stable for a few weeks refrigerated; bacteriostatic water itself has a limited (~28-day) in-use window. Do not use if powder shows moisture, yellowing, or fails to fully dissolve. Each reconstitution introduces contamination risk, especially for an intranasal product.

What people report

Volume of reports: moderate. A real body of reports, fairly consistent.

Moderate. Selank has a sizable, long-running footprint in nootropic and biohacker communities (often discussed alongside Semax), more than most obscure peptides but far less than mainstream supplements, a steady stream of forum reports and reviews rather than a flood.

Reasonably consistent in direction: most positive reports describe a subtle 'takes the edge off,' calmer-but-clear, slightly improved focus effect rather than anything dramatic. A meaningful minority report little or no effect and openly wonder whether it is placebo. Few report strong or unpleasant effects, which fits the gentle profile but also fits a weak-signal compound.

Mixed and to be discounted. Much of the online content is published by peptide vendors and affiliate sites with a financial interest, which inflates apparent enthusiasm; independent user anecdotes are genuine but subjective and prone to expectancy bias. The credible end of the signal is the small body of Russian clinical reports, not the forum chatter.

• Many users describe a mild, takes-the-edge-off calm without sedation, 'quieter mental chatter' and feeling less reactive to stress while staying clear-headed and able to work (anecdote, not proof).
• A common theme is that it is subtle and stacks well with Semax; people often credit the Semax+Selank combo for focus and calm, which makes Selank's individual contribution hard to isolate (anecdote).
• A notable minority report feeling little or nothing and explicitly question whether their response is placebo, sometimes after a single short cycle (anecdote).
• Users generally report it as well tolerated, with the most frequent complaint being nasal/sinus irritation or a mild headache from the intranasal spray rather than any systemic effect (anecdote).

Reports are anecdote, not proof.

Can you tell if it is working?

First documented human use: First documented human clinical use traces to Russian trials in the 1990s-2000s at the V.V. Zakusov Research Institute of Pharmacology (Moscow); the earliest PubMed-indexed human anxiety trial is 2008 (n=62, selank vs the benzodiazepine medazepam in generalized anxiety disorder and neurasthenia). Important caveat: NO double-blind, placebo-controlled randomized trial of Selank has ever been completed or indexed, all published human trials are open-label or active-comparator designs, and there are no Selank-specific registrations on ClinicalTrials.gov.

1. 1990sDeveloped at the Institute of Molecular Genetics, Russian Academy of Sciences, by extending the immune peptide tuftsin (Thr-Lys-Pro-Arg) with Pro-Gly-Pro for metabolic stability; clinical development with the V.V. Zakusov Research Institute of Pharmacology.
2. 2008Earliest PubMed-indexed human anxiety trial (n=62): Selank vs medazepam in GAD and neurasthenia, reporting comparable anxiolytic effect without sedation.
3. 2014Comparative clinical trial (n=60) of Selank vs phenazepam in phobic-anxiety disorders published in the Korsakov journal.
4. 2015Trial of Selank as augmentation to phenazepam monotherapy for anxiety disorders.
5. 2020Functional-connectomic neuroimaging study of Selank and Semax in ~52 healthy participants.
6. 2024-09-27FDA removed Selank acetate from Category 2 of the interim 503A bulks list (following nominator withdrawal); remains unapproved and US-marketed as research-only.

• PubMed, selank anxiety (human trials)(Confirms small Russian clinical trials (2008 n=62 vs medazepam; 2014 n=60 vs phenazepam; 2015 augmentation). Active-comparator, not placebo-controlled.)
• PubMed, selank placebo double-blind (0 results)(Returns zero results, no double-blind, placebo-controlled trial is indexed.)
• PubMed, selank (full literature)(~135 results, predominantly animal/in-vitro/mechanistic plus a few small human studies.)
• ClinicalTrials.gov, selank(No Selank-specific registered trials; only incidental keyword co-occurrence matches.)
• DailyMed/FDA, selank search(No FDA-approved labeling; confirms unapproved status in the US.)
• Wikipedia. Selank(Sequence (TKPRPGP), tuftsin derivation, Institute of Molecular Genetics origin, Russian/Ukrainian pharmacy availability.)
• Zozulia AA et al. Zh Nevrol Psikhiatr Im S S Korsakova 2008;108(4):38-48 (PMID 18454096)(dose table)
• Medvedev VE et al. Zh Nevrol Psikhiatr Im S S Korsakova 2014;114(7):17-22 (PMID 25176261)(dose table)
• Medvedev VE et al. Zh Nevrol Psikhiatr Im S S Korsakova 2015;115(6):33-40 (PMID 26356395)(dose table)